NovaDel Pharma Inc. To Present at the SCIA National Investment Conference
Posted on: Friday, 23 September 2005, 18:00 CDT
NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company with an oral spray technology applicable to a broad array of therapeutic areas and product categories, will be exhibiting at the Southern California Investment Association's National Investment Conference. The conference will be held from 7:15am to 2:00pm on October 1, 2005 at the Orange County Airport Hilton in Irvine, California. Michael Spicer, Chief Financial Officer of NovaDel, will provide an overview of NovaDel's pipeline of novel patent protected products.
About NovaDel Pharma, Inc.
NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient the potential for (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. To find out more about NovaDel Pharma Inc. (AMEX: NVD), visit our website at www.novadel.com.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the successful completion of its pilot pharmacokinetic feasibility studies, the ability to develop products (independently and through collaborative arrangements), the ability to commercialize and obtain FDA and other regulatory approvals for products under development and the acceptance in the marketplace for lingual spray products. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings.
Source: Business Wire
Related Articles
- Sucampo Pharma, Ltd., A Subsidiary of Sucampo Pharmaceuticals, Inc., Announces Start of Phase 2b Study in Japan to Evaluate Lubiprostone for Chronic Idiopathic Constipation
- FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
- Sucampo Pharma, Ltd., A Subsidiary of Sucampo Pharmaceuticals, Inc. Appoints Kunihiko Soneoka As President and CEO
- Pharmaceutical Production in Hungary is Specialised in the Production of Generic Drugs With Nearly 20 Original Molecules Developed During the Last Decade
- Isis Pharmaceuticals Licenses Anti-HIV Drug to ImQuest Pharmaceuticals
- GTC Biotherapeutics Enters Agreement for Further Clinical Production of MM-093 for Merrimack Pharmaceuticals
- Encysive Pharmaceuticals Announces Presentation/Webcast at the Banc of America Securities Specialty Pharmaceuticals Conference
- Noven to Present at Banc of America Securities Specialty Pharmaceuticals Conference
- First Horizon to Present At the Banc of America Securities Specialty Pharmaceuticals Conference
- Indevus Announces Closing of SANCTURA(R) Transaction; SANCTURA Marketing Rights Acquired By Esprit Pharma (Formerly Known As Saturn Pharmaceuticals)
 |
 |
User Comments (0)
RSS Feeds